| AASLD

Home

CL-ART: A NOVEL SMARTPHONE APPLICATION THAT CAN HELP PREDICT FUTURE HOSPITALISATION SECONDARY TO CIRRHOSIS ACUTE DECOMPENSATION.

Read more about CL-ART: A NOVEL SMARTPHONE APPLICATION THAT CAN HELP PREDICT FUTURE HOSPITALISATION SECONDARY TO CIRRHOSIS ACUTE DECOMPENSATION.

<div>Background: Hepatic encephalopathy (HE) is the most frequent cirrhosis complication leading to hospital admissions and is associated with significant mortality. The aim of this study was to determine the ability of the CyberLiver-Animal Recognition Test (CL-ART) to predict future hospitalisation due to decompensation, especially through HE, comparing its performance to established HE tests.

INTESTINE SPECIFIC HIF-1α OVEREXPRESSION AMELIORATES WESTERN DIET-INDUCED MASLD AND METABOLIC PHENOTYPES

Read more about INTESTINE SPECIFIC HIF-1α OVEREXPRESSION AMELIORATES WESTERN DIET-INDUCED MASLD AND METABOLIC PHENOTYPES

<div>Background: Intestine epithelial HIF-1α plays a critical role in the maintaining of gut barrier function. Disrupted gut barrier function contributes to the development of metabolic syndrome. The aim of this study is to determine whether pharmacological or genetic activation of intestinal HIF-1α ameliorates western diet-induced MASLD and metabolic syndrome.

INCORPORATING ADVANCE CARE PLANNING IN ADULTS WITH DECOMPENSATED CIRRHOSIS AT LIVER TRANSPLANT CENTERS: A NURSING-LED EDUCATIONAL INITIATIVE

Read more about INCORPORATING ADVANCE CARE PLANNING IN ADULTS WITH DECOMPENSATED CIRRHOSIS AT LIVER TRANSPLANT CENTERS: A NURSING-LED EDUCATIONAL INITIATIVE

<div>Background: Clinician inexperience with advanced care planning (ACP) is a barrier to patient-centered care for adults </span&

TARGETING IL-17RA IN HEPATOCYTES AS A NOVEL THERAPEUTICAL APPROACH FOR AALD USING GALNAC DELIVERY SYSTEM

Read more about TARGETING IL-17RA IN HEPATOCYTES AS A NOVEL THERAPEUTICAL APPROACH FOR AALD USING GALNAC DELIVERY SYSTEM

<div>Background: IL-17 signaling is implicated in the pathogenesis of alcohol-associated liver disease (AALD) leading to steatosis, fibrosis and hepatocellular carcinoma (HCC). We recently demonstrated that the specific deletion of IL-17RA in hepatocytes protects from steatosis, fibrosis and HCC in high fat diet plus ethanol (HFD+EtOH)-fed in MUP uPA mice (model that express urokinase-type plasminogen activator driven by a hepatocyte promoter for major urinary protein).

CHOLANGIOCYTE-MEDIATED INFILTRATION OF NEUTROPHILS IN THE PERI-PORTAL REGION INDUCES OXIDATIVE STRESS IN PRIMARY SCLEROSING CHOLANGITIS

Read more about CHOLANGIOCYTE-MEDIATED INFILTRATION OF NEUTROPHILS IN THE PERI-PORTAL REGION INDUCES OXIDATIVE STRESS IN PRIMARY SCLEROSING CHOLANGITIS

<div>Background: Primary Sclerosing Cholangitis (PSC) manifests with fibrotic scarring of the intrahepatic and extrahepatic bile ducts due to an immune-mediated inflammatory response. The cyclic GMP–AMP synthase –stimulator of interferon genes (cGAS-STING) signaling pathway is a key mediator of inflammatory gene expression and cytokine release in response to cellular stress. The inflammatory milieu observed in PSC recruits immune cells, including neutrophils, to infiltrate the peri-portal region.

SPLEEN STIFFNESS MEASUREMENT BY TRANSIENT ELASTOGRAPHY WITH A SPLEEN-DEDICATED MODULE: A PROSPECTIVE PILOT FEASIBILITY STUDY IN A PEDIATRIC COHORT

Read more about SPLEEN STIFFNESS MEASUREMENT BY TRANSIENT ELASTOGRAPHY WITH A SPLEEN-DEDICATED MODULE: A PROSPECTIVE PILOT FEASIBILITY STUDY IN A PEDIATRIC COHORT

<div>Background: Several studies in adults showed that spleen stiffness measurement (SSM) by vibration-controlled transient elastography (VCTE) can accurately assess clinically significant portal hypertension (HTN) and predict presence of esophageal varices. However, pediatric studies on SSM published thus far have used a liver-specific probe to measure the spleen making them difficult to interpret and possibly overestimating SSM, as the spleen is inherently a stiffer organ than the liver.

PREOPERATIVE HEPATOLOGY AND PRIMARY CARE VISITS ARE ASSOCIATED WITH REDUCED POSTOPERATIVE MORTALITY IN PATIENTS WITH CIRRHOSIS UNDERGOING SURGERY: A VETERANS AFFAIRS PROPENSITY MATCHED STUDY

Read more about PREOPERATIVE HEPATOLOGY AND PRIMARY CARE VISITS ARE ASSOCIATED WITH REDUCED POSTOPERATIVE MORTALITY IN PATIENTS WITH CIRRHOSIS UNDERGOING SURGERY: A VETERANS AFFAIRS PROPENSITY MATCHED STUDY

<div>Background: Patients with cirrhosis have increased surgical risk compared to the general population. Preoperative optimization by nonsurgical clinicians improves postoperative outcomes after colectomy in studies of patients with major comorbidities, however, data specific to patients with cirrhosis and addressing more diverse surgeries are limited.

EFFECTIVENESS AND SAFETY OF SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS (PBC): A PROSPECTIVE MULTICENTER REAL-WORLD COHORT.

Read more about EFFECTIVENESS AND SAFETY OF SECOND-LINE THERAPY IN PRIMARY BILIARY CHOLANGITIS (PBC): A PROSPECTIVE MULTICENTER REAL-WORLD COHORT.

<div>Background: About 30% of patients with PBC have a suboptimal response to ursodeoxycholic acid (UDCA), leading to a worse prognosis. In the phase III POISE trial, response to obeticholic acid (OCA) was assessed by using the POISE score. Recently, complete biochemical normalization (normal ALP and bilirubin ≤ 0.6 ULN) has been proposed as a new therapeutic aim in PBC, as it significantly improves liver-related and overall survival, but the effectiveness of second-line therapy for this new therapeutic target has not been evaluated.

LONG TERM HBsAg REDUCTION BY A NASAL ADMINISTRATIVE THERAPEUTIC VACCINE CONTAINING HBsAg AND HBCAG MIXED WITH MUCOADHESIVE CVP IN PATIENTS WITH CHRONIC HBV INFECTION: THE RESULTS OF 48 MONTHS FOLLOW UP

Read more about LONG TERM HBsAg REDUCTION BY A NASAL ADMINISTRATIVE THERAPEUTIC VACCINE CONTAINING HBsAg AND HBCAG MIXED WITH MUCOADHESIVE CVP IN PATIENTS WITH CHRONIC HBV INFECTION: THE RESULTS OF 48 MONTHS FOLLOW UP

<div>Background: We reported the HBsAg reduction by a nasal administrative therapeutic vaccine containing HBsAg/HBcAg mixed with mucoadhesive excipient carboxy-vinyl polymer (CVP-NASVAC) in chronically HBV infected patients. This study was aimed to assess the long-term efficacy of CVP-NASVAC at 48 months after the first 10 doses.

LIVER LYMPHANGIOGENESIS MITIGATES THE PROGRESSION OF FIBROSIS

Read more about LIVER LYMPHANGIOGENESIS MITIGATES THE PROGRESSION OF FIBROSIS

<div>Background: Chronic inflammation due to various etiologies leads to liver fibrosis and subsequently cirrhosis. The liver lymphatic system helps to reduce inflammation. We hypothesized that the liver lymphatic system ameliorates liver fibrosis/cirrhosis.

Subscribe to